Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ServiceNow Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while ServiceNow Inc trades at $138.34 (market cap $143.30B). The key difference: ServiceNow Inc is far larger — about 50.1× Dyne Therapeutics Inc. Common Stock's market cap, and ServiceNow Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and ServiceNow Inc for 54 Days on average.
| DYN | NOW | |
|---|---|---|
Market Cap | $2.86B | $143.30B |
Volume | 3,341,579 | 13,207,010 |
Sector | Health | Technology |
52-Week High | $26.78 | $189.26 |
52-Week Low | $14.60 | $83.00 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $2.18B | $147.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ServiceNow (NOW) trades at $140.32, down 0.38% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.90, and its AI business surpassed $1 billion in annual contract value. Revenue grew to $13.28 billion in 2025, with a net income margin of 11.34%, though valuation multiples remain elevated with a P/E of 86.63.
The outlook is positive, supported by robust AI adoption and enterprise demand, but risks include high valuation, competitive pressures, and potential margin compression. Analysts are overwhelmingly bullish with an 86.96% buy rating and a consensus price target of $150.71, suggesting upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
